Gardos pathway to sickle cell therapies?
- PMID: 18434967
- PMCID: PMC2288713
- DOI: 10.1182/blood-2008-01-135350
Gardos pathway to sickle cell therapies?
Abstract
In this issue of Blood, Ataga and colleagues report that treatment of sickle cell disease patients with senicapoc, a Gardos channel inhibitor, reduces the number of dehydrated cells, increases hemoglobin levels, and diminishes hemolysis.
Conflict of interest statement
Conflict-of-interest disclosure: C.H.J. participated as a site investigator in the phase 3 trial of senicapoc, funded by Icagen (Durham, NC)/McNeil (Fort Washington, PA). He has been a paid consultant for Icagen. ■
Figures
Comment on
-
Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia.Blood. 2008 Apr 15;111(8):3991-7. doi: 10.1182/blood-2007-08-110098. Epub 2008 Jan 11. Blood. 2008. PMID: 18192510 Clinical Trial.
References
Publication types
LinkOut - more resources
Full Text Sources
